NATPARA was studied in a 24-week, randomized, double-blind, placebo-controlled trial in 124 adults with hypoparathyroidism1
Calcium supplements and active vitamin D doses were adjusted to target an albumin-corrected serum calcium concentration between 8.0 and 9.0 mg/dL, and 25-hydroxyvitamin D was replaced in patients with insufficient stores.
Patients were randomized to either 50 mcg of NATPARA (n=84) or placebo (n=40).
At randomization, active forms of vitamin D were reduced by 50%.
TREATMENTNATPARA or Placebo
NATPARA was increased by 25 mcg increments every 4 weeks up to a maximum of 100 mcg, as indicated for patients who could not achieve independence from active vitamin D and who could not reduce oral calcium to 500 mcg or less per day.
The daily dose of NATPARA established during titration could be reduced, but not increased, in this phase2.
Study population1 (NATPARA and Placebo Combined N=124 Patients)
47 (range of 19 to 74 years)
79% female, 21% male
Duration of hypoparathyroidism (mean)
At baseline after optimization with oral calcium and active vitamin D
Daily oral calcium (median)
2000 (1250, 3000) mg
Daily oral vitamin D (median)
0.75 (0.5, 1) mcg calcitrol equivalent
Albumin-correct serum calcium (mean)
Representation of how study participants may have taken oral calcium and active vitamin D throughout the day
References: 1. NATPARA [package insert]. Shire-NPS Pharmaceuticals, Inc. 2. Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013;1(4):275-283. 3. National Institutes of Health. Calcium fact sheet for consumers. https://ods.od.nih.gov/factsheets/Calcium-Consumer/. Updated November 17, 2016. Accessed March 28, 2017.